495 related articles for article (PubMed ID: 20711231)
21. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts.
Tang Y; Chen Z; Ambrose D; Liu J; Gibbs JB; Chernoff J; Field J
Mol Cell Biol; 1997 Aug; 17(8):4454-64. PubMed ID: 9234703
[TBL] [Abstract][Full Text] [Related]
22. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
[TBL] [Abstract][Full Text] [Related]
23. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
24. Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras-related Rho subfamily and its role in phosphorylation signalling pathways.
Lim L; Manser E; Leung T; Hall C
Eur J Biochem; 1996 Dec; 242(2):171-85. PubMed ID: 8973630
[TBL] [Abstract][Full Text] [Related]
25. P21 activated kinase signaling in cancer.
Rane CK; Minden A
Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
[TBL] [Abstract][Full Text] [Related]
26. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
27. Trihydrophobin 1 Interacts with PAK1 and Regulates ERK/MAPK Activation and Cell Migration.
Cheng C; Kong X; Wang H; Gan H; Hao Y; Zou W; Wu J; Chi Y; Yang J; Hong Y; Chen K; Gu J
J Biol Chem; 2009 Mar; 284(13):8786-96. PubMed ID: 19136554
[TBL] [Abstract][Full Text] [Related]
28. The PAK system links Rho GTPase signaling to thrombin-mediated platelet activation.
Aslan JE; Baker SM; Loren CP; Haley KM; Itakura A; Pang J; Greenberg DL; David LL; Manser E; Chernoff J; McCarty OJ
Am J Physiol Cell Physiol; 2013 Sep; 305(5):C519-28. PubMed ID: 23784547
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
Lu Y; Zi X; Zhao Y; Pollak M
Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
[TBL] [Abstract][Full Text] [Related]
30. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
[TBL] [Abstract][Full Text] [Related]
31. ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression.
Rafn B; Nielsen CF; Andersen SH; Szyniarowski P; Corcelle-Termeau E; Valo E; Fehrenbacher N; Olsen CJ; Daugaard M; Egebjerg C; Bøttzauw T; Kohonen P; Nylandsted J; Hautaniemi S; Moreira J; Jäättelä M; Kallunki T
Mol Cell; 2012 Mar; 45(6):764-76. PubMed ID: 22464443
[TBL] [Abstract][Full Text] [Related]
32. H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells.
Shin I; Kim S; Song H; Kim HR; Moon A
J Biol Chem; 2005 Apr; 280(15):14675-83. PubMed ID: 15677464
[TBL] [Abstract][Full Text] [Related]
33. Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.
Ward TM; Iorns E; Liu X; Hoe N; Kim P; Singh S; Dean S; Jegg AM; Gallas M; Rodriguez C; Lippman M; Landgraf R; Pegram MD
Oncogene; 2013 May; 32(19):2463-74. PubMed ID: 22751112
[TBL] [Abstract][Full Text] [Related]
34. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
35. Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis.
Bigi A; Beltrami E; Trinei M; Stendardo M; Pelicci PG; Giorgio M
Oncogene; 2016 Sep; 35(39):5132-43. PubMed ID: 26973251
[TBL] [Abstract][Full Text] [Related]
36. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation.
He H; Hirokawa Y; Manser E; Lim L; Levitzki A; Maruta H
Cancer J; 2001; 7(3):191-202. PubMed ID: 11419027
[TBL] [Abstract][Full Text] [Related]
37. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
38. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
Wang LH; Chan JL; Li W
Int J Cancer; 2007 Jul; 121(1):157-64. PubMed ID: 17304506
[TBL] [Abstract][Full Text] [Related]
39. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L; Xiang B; Muthuswamy SK
Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
[TBL] [Abstract][Full Text] [Related]
40. Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis.
Taliaferro-Smith L; Nagalingam A; Knight BB; Oberlick E; Saxena NK; Sharma D
Neoplasia; 2013 Jan; 15(1):23-38. PubMed ID: 23358729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
